Newswise — BIRMINGHAM, Ala. – The University of Alabama at Birmingham Division of Clinical Immunology and Rheumatology begins a phase two proof-of-concept clinical trial evaluating the use of the immunomodulator mycophenolate mofetil, or MMF, with Horizon Pharma plc’s KRYSTEXXA® (pegloticase injection) to persistently lower the serum uric acid for patients living with uncontrolled gout.
REducing Immunogenicity to PegloticasE (RECIPE) is a double-blind, placebo controlled, phase two trial designed to evaluate whether a 12-week course of immune-modulating therapy with daily MMF can safely and meaningfully induce an immune response to KRYSTEXXA as well as assess the incidence and types of adverse events and infusion reactions.
Kenneth Saag, M.D., principal investigator and director of the UAB Center of Research Translation in Gout and Hyperuricemia says rheumatologists have a high degree of familiarity and comfort using MMF as an immunomodulator in combination with other medications, as well as a favorable view of the medicine‘s potential to reduce or prevent the development of antidrug antibodies with pegloticase.
“As a practicing physician at one of the leading centers for gout research, I have seen the profound impact uncontrolled gout can have on those living with the disease,” Saag said. “Given the significant health burden caused by this disease, evaluating new ways to improve the response rate for pegloticase will advance disease understanding and ultimately help more patients benefit from this underutilized therapy.”
KRYSTEXXA is the only biologic approved by the U.S. Food and Drug Administration for adults living with uncontrolled gout, a painful and debilitating inflammatory condition with which people continue to have abnormally high levels of uric acid and symptoms despite the use of conventional therapies.
Data from the KRYSTEXXA pivotal clinical trials show that 42 percent of the people treated with the pegloticase injection achieved complete response, with sUA levels less than 6 mg/dL throughout the trials, and that many also had complete resolution of tophi.
“As with many biologic medicines, some people treated with KRYSTEXXA can develop antidrug antibodies as a part of an immune response to the medicine, known as immunogenicity, and lose response to therapy,” said Jeffrey W. Sherman, M.D., executive vice president and chief medical officer, Horizon Pharma plc. “The application of sUA stopping rules for those who develop antidrug antibodies has meaningfully reduced infusion reactions, and this trial builds on these insights, as it evaluates one way to address immunogenicity and potentially enables KRYSTEXXA to work for a longer period of time in more people with uncontrolled gout.”
Those who meet RECIPE (NCT03303989) phase two eligibility criteria will be randomized three to one to receive 12 infusions of KRYSTEXXA with MMF or KRYSTEXXA with placebo every two weeks for 12 weeks. After the initial 12 weeks of therapy, patients will continue on KRYSTEXXA-only therapy for an additional 12 weeks.
The primary endpoint will be determined by the proportion of people participating in the study achieving and maintaining sUA less than or equal to 6 mg/dL through 12 weeks, compared to concurrent controls receiving KRYSTEXXA but not MMF.
In addition, the RECIPE trial will measure several secondary endpoints at week 24, including durability of immunomodulatory effect after MMF discontinuation and patient-reported outcomes using the National Institutes of Health-supported Patient Reported Outcomes Measurement Information System and Gout Impact Scale. Safety will also be evaluated.
Along with UAB, the University of Michigan and several other academic and private practice sites will enroll a total of 32 people living with uncontrolled gout in the RECIPE trial. More detailed information about this study, including eligibility requirements, as well as other uncontrolled gout studies including Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect (TRIPLE), is available at ClinicalTrials.gov.
Known for its innovative and interdisciplinary approach to education at both the graduate and undergraduate levels, the University of Alabama at Birmingham is the state of Alabama’s largest employer and an internationally renowned research university and academic medical center; its professional schools and specialty patient-care programs are consistently ranked among the nation’s top 50. Find more information at www.uab.edu and www.uabmedicine.org.
*KRYSTEXXA is a registered trademark of Horizon Rheumatology LLC.
EDITOR’S NOTE: The University of Alabama at Birmingham is a separate, independent institution from the University of Alabama, which is located in Tuscaloosa. Please use University of Alabama at Birmingham on first reference and UAB on all subsequent references.